Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo de estudio
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Infect Dis ; 61 Suppl 5: S554-62, 2015 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-26553688

RESUMEN

BACKGROUND: PsA-TT (MenAfriVac) is a conjugated polysaccharide vaccine developed to eliminate group A meningococcal disease in Africa. Vaccination of African study participants with 1 dose of PsA-TT led to the production of anti-A polysaccharide antibodies and increased serum bactericidal activity measured using rabbit complement (rSBA). Bactericidal responses measured with human complement (hSBA) are presented here. METHODS: Sera collected before and at 28 days and 1 year after vaccination with either PsA-TT or quadrivalent polysaccharide vaccine (PsACWY) from a random, age-distributed 360-subject subset of the Meningitis Vaccine Project study of PsA-TT in Africans aged 2-29 years were tested for hSBA. Geometric mean titer, fold-rise, and threshold analyses were compared between vaccine groups and age groups. hSBA, rSBA, and immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) results were compared and assay correlation and agreement determined. RESULTS: hSBA responses to PsA-TT were substantially higher than those to PsACWY at 28 days and 1 year following immunization, similar to previously reported rSBA and IgG results. The hSBA and IgG ELISA results identified differences between age groups that were not evident by rSBA. The rSBA data indicated sustained high titers 1 year after immunization, whereas hSBA GMTs at 1 year approached 4 in young children. CONCLUSIONS: The high level of protection following PsA-TT immunization campaigns is consistent with the strong hSBA immune responses observed here. Future implementation decisions will likely depend on immunologic data and their long-term correlation with disease and carriage prevention. Expanded immunologic and epidemiologic surveillance may improve the interpretation of differences between these immunoassays.


Asunto(s)
Anticuerpos Antibacterianos/sangre , Actividad Bactericida de la Sangre , Proteínas del Sistema Complemento , Inmunoensayo/métodos , Vacunas Meningococicas/inmunología , Neisseria meningitidis Serogrupo A/inmunología , Adolescente , Adulto , África , Animales , Niño , Preescolar , Humanos , Inmunoglobulina G/sangre , Vacunas Meningococicas/administración & dosificación , Conejos , Adulto Joven
2.
Virol J ; 3: 105, 2006 Dec 27.
Artículo en Inglés | MEDLINE | ID: mdl-17192179

RESUMEN

BACKGROUND: Herpes simplex virus (HSV) can utilize multiple pathways to enter host cells. The factors that determine which route is taken are not clear. Chinese hamster ovary (CHO) cells that express glycoprotein D (gD)-binding receptors are model cells that support a pH-dependent, endocytic entry pathway for all HSV strains tested to date. Fusion-from-without (FFWO) is the induction of target cell fusion by addition of intact virions to cell monolayers in the absence of viral protein expression. The receptor requirements for HSV-induced FFWO are not known. We used the syncytial HSV-1 strain ANG path as a tool to evaluate the complex interplay between receptor usage, membrane fusion, and selection of entry pathway. RESULTS: Inhibitors of endocytosis and endosome acidification blocked ANG path entry into CHO cells expressing nectin-1 receptors, but not CHO-nectin-2 cells. Thus, under these conditions, nectin-2 mediates pH-independent entry at the plasma membrane. In addition, CHO-nectin-2 cells supported pH-dependent, endocytic entry of different strains of HSV-1, including rid1 and HFEM. The kinetics of ANG path entry was rapid (t1/2 of 5-10 min) regardless of entry route. However, HSV-1 ANG path entry by fusion with the CHO-nectin-2 cell plasma membrane was more efficient and resulted in larger syncytia. ANG path virions added to the surface of CHO-nectin-2 cells, but not receptor-negative CHO cells or CHO-nectin-1 cells, induced rapid FFWO. CONCLUSION: HSV-1 ANG path can enter CHO cells by either endocytic or non-endocytic pathways depending on whether nectin-1 or nectin-2 is present. In addition to these cellular receptors, one or more viral determinants is important for the selection of entry pathway. HSV-induced FFWO depends on the presence of an appropriate gD-receptor in the target membrane. Nectin-1 and nectin-2 target ANG path to divergent cellular pathways, and these receptors may have different roles in triggering viral membrane fusion.


Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Células Gigantes/fisiología , Herpesvirus Humano 1/patogenicidad , Fusión de Membrana/fisiología , Receptores Virales/metabolismo , Animales , Células CHO , Moléculas de Adhesión Celular/farmacología , Membrana Celular/virología , Chlorocebus aethiops , Cricetinae , Cricetulus , Herpesvirus Humano 1/fisiología , Concentración de Iones de Hidrógeno , Nectinas , Células Vero , Proteínas del Envoltorio Viral/metabolismo , Virión/metabolismo , Virión/patogenicidad
3.
Vaccine ; 25(41): 7247-60, 2007 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-17720283

RESUMEN

We have previously demonstrated the full-length gonococcal transferrin binding proteins (TbpA and TbpB) to be promising antigens in the development of a protective vaccine against Neisseria gonorrhoeae. In the current study we employed a genetic chimera approach fusing domains from TbpA and TbpB to the A2 domain of cholera toxin, which naturally binds in a non-covalent fashion to the B subunit of cholera toxin during assembly. For one construct, the N-terminal half of TbpB (NB) was fused to the A2 subunit of cholera toxin. In a second construct, the loop 2 region (L2) of TbpA was genetically fused between the NB domain and the A2 domain, generating a double chimera. Both chimeras were immunogenic and induced serum bactericidal and vaginal growth-inhibiting antibodies. This study highlights the potential of using protective epitopes instead of full-length proteins in the development of an efficacious gonococcal vaccine.


Asunto(s)
Anticuerpos Antibacterianos/inmunología , Gonorrea/prevención & control , Viabilidad Microbiana/inmunología , Neisseria gonorrhoeae/crecimiento & desarrollo , Neisseria gonorrhoeae/inmunología , Proteína A de Unión a Transferrina/inmunología , Proteína B de Unión a Transferrina/inmunología , Secuencia de Aminoácidos , Animales , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Toxina del Cólera/química , Toxina del Cólera/genética , Toxina del Cólera/inmunología , ADN Bacteriano/química , ADN Bacteriano/genética , Femenino , Gonorrea/inmunología , Ratones , Datos de Secuencia Molecular , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Análisis de Secuencia de ADN , Proteína A de Unión a Transferrina/química , Proteína A de Unión a Transferrina/genética , Proteína B de Unión a Transferrina/química , Proteína B de Unión a Transferrina/genética , Vagina/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA